trial

Diabetes Screening, Risk Management and Disease Management in a High-Risk Mental Health Population Part II

NCTId NCT00377117
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase — · Completed
Enrollment 39 (actual)
Sponsored by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
39 (actual)
Study type
Observational
Allocation
—
Model
—
Masking
—
Start
2006-05
Primary completion
—
Eligibility
ALL · 18 Years · 75 Years

Interventions & indications

Drugs
ManagementScreening

Sponsors

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sLead Sponsor
Eli Lilly and CompanyCollaborator
St. Joseph's Health Care LondonCollaborator

Investigators

2
Stewart B Harris, MD MPH CCFP FACPMPrincipal Investigator
David RS Haslam, MSc MD FRCPCPrincipal Investigator

Sites

1 total
London, Canada

Facts & assertions

3 sourced
Enrollment
39
Phase
NA
Status
COMPLETED
relationships
The graph out of here
drug
Management
drug
Screening
drug
lead_sponsor
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
company
collaborator
Eli Lilly and Company
company
St. Joseph's Health Care London
company
indication
Psychotic Disorders
indication
Diabetes Mellitus
indication
Diabetes Mellitus
indication
investigator
Stewart B Harris, MD MPH CCFP FACPM
person
David RS Haslam, MSc MD FRCPC
person